US OptionsDetailed Quotes
SPRY250516C15000
- 0.32
- 0.000.00%
15min DelayClose May 9 16:00 ET
0.40High0.32Low
0.40Open0.32Pre Close66 Volume415 Open Interest15.00Strike Price2.15KTurnover134.01%IV13.99%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.32Extrinsic Value100Contract SizeAmericanOptions Type0.2791Delta0.1528Gamma38.40Leverage Ratio-0.0701Theta0.0005Rho10.72Eff Leverage0.0055Vega
ARS Pharmaceuticals Stock Discussion
just
ARS Pharmaceuticals Announces Co-Promotion Agreement With Partner and Global Allergy Leader Alk-Abelló A/S to Expand Reach of Neffy® (Epinephrine Nasal Spray) to Additional U.S. Pediatricians.
Reuters· 3 mins ago
ARS Pharmaceuticals Inc - Pharma Received $145 Million Upfront From Alk
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) is a biopharmaceutical company focused on developing and commercializing neffy, a needle-free intranasal epinephrine spray designed for emergency treatment of Type I allergic reactions, including anaphylaxis. Below is an analysis of SPRY stock based on available data as of March 17, 2025:
### Company Overview
- Product: Neffy is the first FDA-approved needle-free epinephrine delivery system, offering an al...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If y...
just
ARS Pharmaceuticals Announces FDA Approval of Neffy® 1 Mg (Epinephrine Nasal Spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
Positive
First FDA-approved needle-free epinephrine nasal spray
Rapid inclusion on Express Scripts Commercial National Formularies (9 weeks post-launch)
Access to millions of commercially insured patients
Superior product features: 30-month shelf-life, high temperature tolerance (122°F)
Negative
to patients weighing ≥30 kg (66 lbs.)
Current...
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
Agreement leverages ALK's global footprint in developing and commercializing innovative allergy products
ARS Pharma to receive an upfront cash payment of $145 million, with total deal consideration of up to $465 million plus double-digit royalties on net sales
ARS Pharma retains all U.S. rig...
No comment yet